HIMS News & Analysis
3 articles
Market Mood
Hims & Hers (HIMS) shares rise 8% amid FDA review of peptides
Shares of Hims & Hers Health (HIMS) increased by over 8% to approximately $26 following the FDA's announcement to initiate a formal review of wellness peptides. The review includes potential inclusion of multiple peptide-related substances on the 503A bulks list. Bank of America raised its price target for HIMS from $21 to $25 while maintaining a 'Neutral' rating. While the review process introduces strategic optionality for HIMS, the immediate impact on earnings remains uncertain, contingent upon future FDA decisions.
Read More
HIMS stock gains as U.S. reassesses peptide sales plan
Hims & Hers Health (HIMS) has seen an increase in its stock value following developments in the U.S. regarding the reassessment of popular peptide sales. This shift indicates a potential expansion opportunity for HIMS in the peptide market, which could positively influence its revenue streams. The company’s entry into this segment could align with increasing consumer interest in peptide products. Monitoring this development will be crucial for investors focused on HIMS's growth potential.
Read More
FDA Weighs Lifting Peptide Restrictions Impacting HIMS
The FDA is considering easing restrictions on certain peptides, which could affect the market for companies like Hims & Hers (HIMS). This follows growing interest in wellness products associated with these peptides. A meeting is scheduled for a panel to discuss broader access, which if approved could drive sales and market interest. The potential easing of regulations signifies a notable shift in health product availability that may impact HIMS stock prices and market strategies.
Read More